147 related articles for article (PubMed ID: 11489833)
21. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
Wu L; Tannock IF
Clin Cancer Res; 2005 Nov; 11(22):8195-200. PubMed ID: 16299252
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Jordan VC; Gosden B
Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
[TBL] [Abstract][Full Text] [Related]
23. Role of estrogen receptors and antiestrogen binding sites in an early effect of antiestrogens, the inhibition of cholesterol biosynthesis.
Cypriani B; Tabacik C; Descomps B; Crastes de Paulet A
J Steroid Biochem; 1988 Nov; 31(5):763-71. PubMed ID: 3199816
[TBL] [Abstract][Full Text] [Related]
24. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
25. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
26. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms.
Black LJ; Goode RL
Endocrinology; 1981 Sep; 109(3):987-9. PubMed ID: 7262030
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen and the Rafoxifene analog LY117018: their effects on arachidonic acid release from cells in culture and on prostaglandin I2 production by rat liver cells.
Levine L
BMC Cancer; 2004 Aug; 4():49. PubMed ID: 15310397
[TBL] [Abstract][Full Text] [Related]
28. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):129-38. PubMed ID: 7981453
[TBL] [Abstract][Full Text] [Related]
29. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Licun W; Tannock IF
Clin Cancer Res; 2003 Oct; 9(12):4614-8. PubMed ID: 14555537
[TBL] [Abstract][Full Text] [Related]
30. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
[TBL] [Abstract][Full Text] [Related]
31. Molecular effects of antiestrogens (tamoxifen and LY117018) on estrogen-dependent glycoprotein (USP-1) synthesized and secreted by rat uterine epithelial cells.
Takeda A; Shimizu S
Endocrinology; 1988 Jul; 123(1):258-63. PubMed ID: 3383775
[TBL] [Abstract][Full Text] [Related]
32. COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro.
Du Y; Shi A; Han B; Li S; Wu D; Jia H; Zheng C; Ren L; Fan Z
Int J Oncol; 2014 Apr; 44(4):1385-93. PubMed ID: 24535190
[TBL] [Abstract][Full Text] [Related]
33. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.
Ju YH; Doerge DR; Allred KF; Allred CD; Helferich WG
Cancer Res; 2002 May; 62(9):2474-7. PubMed ID: 11980635
[TBL] [Abstract][Full Text] [Related]
34. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.
Molloy ME; White BE; Gherezghiher T; Michalsen BT; Xiong R; Patel H; Zhao H; Maximov PY; Jordan VC; Thatcher GR; Tonetti DA
Mol Cancer Ther; 2014 Nov; 13(11):2515-26. PubMed ID: 25205655
[TBL] [Abstract][Full Text] [Related]
35. Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
Jordan VC; Gosden B
J Steroid Biochem; 1983 Sep; 19(3):1249-58. PubMed ID: 6684713
[TBL] [Abstract][Full Text] [Related]
36. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
37. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.
Yu J; Eto M; Kozaki K; Akishita M; Okabe T; Ouchi Y
Eur J Pharmacol; 2008 Jul; 589(1-3):32-6. PubMed ID: 18541231
[TBL] [Abstract][Full Text] [Related]
38. Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast.
Irie T; Takahata M; Majima T; Abe Y; Komatsu M; Iwasaki N; Minami A
Connect Tissue Res; 2010 Jun; 51(3):179-87. PubMed ID: 20073985
[TBL] [Abstract][Full Text] [Related]
39. Raloxifene analog LY117018 enhances the regeneration of sciatic nerve in ovariectomized female mice.
McMurray R; Islamov R; Murashov AK
Brain Res; 2003 Aug; 980(1):140-5. PubMed ID: 12865169
[TBL] [Abstract][Full Text] [Related]
40. Effects of oestrogen and the antioestrogens, tamoxifen and LY117018, on four oestrogen-regulated RNAs in the EFM-19 breast cancer cell line.
Westley BR; Hölzel F; May FE
J Steroid Biochem; 1989 Mar; 32(3):365-72. PubMed ID: 2468045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
